Treatment of social phobia with clonazepam and placebo
Clonazepam and placebo were administered in a double-blind pilot study to 75 outpatients with social phobia. The mean maximum dose of clonazepam was 2.4 mg/day at endpoint (range, 0.5 to 3 mg). Treatment was continued for up to 10 weeks. The results of an intent-to-treat analysis indicated superior...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical psychopharmacology 1993-12, Vol.13 (6), p.423-428 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 428 |
|---|---|
| container_issue | 6 |
| container_start_page | 423 |
| container_title | Journal of clinical psychopharmacology |
| container_volume | 13 |
| creator | DAVIDSON, J. R. T POTTS, N RICHICHI, E KRISHNAN, R FORD, S. M SMITH, R WILSON, W. H |
| description | Clonazepam and placebo were administered in a double-blind pilot study to 75 outpatients with social phobia. The mean maximum dose of clonazepam was 2.4 mg/day at endpoint (range, 0.5 to 3 mg). Treatment was continued for up to 10 weeks. The results of an intent-to-treat analysis indicated superior effects of clonazepam on most measures. Response rates for clonazepam and placebo were 78.3 and 20.0%. Drug effects were apparent on performance and generalized social anxiety, on fear and phobic avoidance, on interpersonal sensitivity, on fears of negative evaluation, and on disability measures. Significant differences were evident by week 1, 2, or 6, depending upon the rating scale used. Clonazepam was well tolerated in general, although unsteadiness and dizziness were more severe and persistent than was the case for placebo subjects. |
| doi_str_mv | 10.1097/00004714-199312000-00008 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00004714_199312000_00008</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>8120156</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-b9ef61f299be8b5e6d9a439c12934943a544a351bc79f1ef7b841925416bbc763</originalsourceid><addsrcrecordid>eNo9j0tLxDAQx3NQ1nX1Iwg5eK1mkjSPoyy-YMHLei6TNGErfdFURD-9Xbd2LsP8HwM_QiiwO2BW37NppAaZgbUC-HRlR8mckTXjGjKmpb0glyl9MAZS83xFVmbKQa7WRO2HgGMT2pF2kabOV1jT_tC5CulXNR6or7sWf0KPDcW2pH2NPrjuipxHrFO4nveGvD897rcv2e7t-XX7sMu8UGbMnA1RQeTWumBcHlRpUQrrgVshrRSYS4kiB-e1jRCidkaC5bkE5SZNiQ0xp79-6FIaQiz6oWpw-C6AFUf64p--WOj_JDNVb07V_tM1oVyKM_rk384-Jo91HLD1VVpiwmgFXItf65Ritg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment of social phobia with clonazepam and placebo</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>DAVIDSON, J. R. T ; POTTS, N ; RICHICHI, E ; KRISHNAN, R ; FORD, S. M ; SMITH, R ; WILSON, W. H</creator><creatorcontrib>DAVIDSON, J. R. T ; POTTS, N ; RICHICHI, E ; KRISHNAN, R ; FORD, S. M ; SMITH, R ; WILSON, W. H</creatorcontrib><description>Clonazepam and placebo were administered in a double-blind pilot study to 75 outpatients with social phobia. The mean maximum dose of clonazepam was 2.4 mg/day at endpoint (range, 0.5 to 3 mg). Treatment was continued for up to 10 weeks. The results of an intent-to-treat analysis indicated superior effects of clonazepam on most measures. Response rates for clonazepam and placebo were 78.3 and 20.0%. Drug effects were apparent on performance and generalized social anxiety, on fear and phobic avoidance, on interpersonal sensitivity, on fears of negative evaluation, and on disability measures. Significant differences were evident by week 1, 2, or 6, depending upon the rating scale used. Clonazepam was well tolerated in general, although unsteadiness and dizziness were more severe and persistent than was the case for placebo subjects.</description><identifier>ISSN: 0271-0749</identifier><identifier>DOI: 10.1097/00004714-199312000-00008</identifier><identifier>PMID: 8120156</identifier><identifier>CODEN: JCPYDR</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Anxiety - drug therapy ; Biological and medical sciences ; Clonazepam - administration & dosage ; Clonazepam - adverse effects ; Clonazepam - therapeutic use ; Double-Blind Method ; Female ; Humans ; Male ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Phobic Disorders - drug therapy ; Phobic Disorders - psychology ; Pilot Projects ; Psychiatric Status Rating Scales ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology</subject><ispartof>Journal of clinical psychopharmacology, 1993-12, Vol.13 (6), p.423-428</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-b9ef61f299be8b5e6d9a439c12934943a544a351bc79f1ef7b841925416bbc763</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3876127$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8120156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DAVIDSON, J. R. T</creatorcontrib><creatorcontrib>POTTS, N</creatorcontrib><creatorcontrib>RICHICHI, E</creatorcontrib><creatorcontrib>KRISHNAN, R</creatorcontrib><creatorcontrib>FORD, S. M</creatorcontrib><creatorcontrib>SMITH, R</creatorcontrib><creatorcontrib>WILSON, W. H</creatorcontrib><title>Treatment of social phobia with clonazepam and placebo</title><title>Journal of clinical psychopharmacology</title><addtitle>J Clin Psychopharmacol</addtitle><description>Clonazepam and placebo were administered in a double-blind pilot study to 75 outpatients with social phobia. The mean maximum dose of clonazepam was 2.4 mg/day at endpoint (range, 0.5 to 3 mg). Treatment was continued for up to 10 weeks. The results of an intent-to-treat analysis indicated superior effects of clonazepam on most measures. Response rates for clonazepam and placebo were 78.3 and 20.0%. Drug effects were apparent on performance and generalized social anxiety, on fear and phobic avoidance, on interpersonal sensitivity, on fears of negative evaluation, and on disability measures. Significant differences were evident by week 1, 2, or 6, depending upon the rating scale used. Clonazepam was well tolerated in general, although unsteadiness and dizziness were more severe and persistent than was the case for placebo subjects.</description><subject>Adult</subject><subject>Anxiety - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Clonazepam - administration & dosage</subject><subject>Clonazepam - adverse effects</subject><subject>Clonazepam - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Phobic Disorders - drug therapy</subject><subject>Phobic Disorders - psychology</subject><subject>Pilot Projects</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><issn>0271-0749</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9j0tLxDAQx3NQ1nX1Iwg5eK1mkjSPoyy-YMHLei6TNGErfdFURD-9Xbd2LsP8HwM_QiiwO2BW37NppAaZgbUC-HRlR8mckTXjGjKmpb0glyl9MAZS83xFVmbKQa7WRO2HgGMT2pF2kabOV1jT_tC5CulXNR6or7sWf0KPDcW2pH2NPrjuipxHrFO4nveGvD897rcv2e7t-XX7sMu8UGbMnA1RQeTWumBcHlRpUQrrgVshrRSYS4kiB-e1jRCidkaC5bkE5SZNiQ0xp79-6FIaQiz6oWpw-C6AFUf64p--WOj_JDNVb07V_tM1oVyKM_rk384-Jo91HLD1VVpiwmgFXItf65Ritg</recordid><startdate>19931201</startdate><enddate>19931201</enddate><creator>DAVIDSON, J. R. T</creator><creator>POTTS, N</creator><creator>RICHICHI, E</creator><creator>KRISHNAN, R</creator><creator>FORD, S. M</creator><creator>SMITH, R</creator><creator>WILSON, W. H</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19931201</creationdate><title>Treatment of social phobia with clonazepam and placebo</title><author>DAVIDSON, J. R. T ; POTTS, N ; RICHICHI, E ; KRISHNAN, R ; FORD, S. M ; SMITH, R ; WILSON, W. H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-b9ef61f299be8b5e6d9a439c12934943a544a351bc79f1ef7b841925416bbc763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adult</topic><topic>Anxiety - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Clonazepam - administration & dosage</topic><topic>Clonazepam - adverse effects</topic><topic>Clonazepam - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Phobic Disorders - drug therapy</topic><topic>Phobic Disorders - psychology</topic><topic>Pilot Projects</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DAVIDSON, J. R. T</creatorcontrib><creatorcontrib>POTTS, N</creatorcontrib><creatorcontrib>RICHICHI, E</creatorcontrib><creatorcontrib>KRISHNAN, R</creatorcontrib><creatorcontrib>FORD, S. M</creatorcontrib><creatorcontrib>SMITH, R</creatorcontrib><creatorcontrib>WILSON, W. H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of clinical psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DAVIDSON, J. R. T</au><au>POTTS, N</au><au>RICHICHI, E</au><au>KRISHNAN, R</au><au>FORD, S. M</au><au>SMITH, R</au><au>WILSON, W. H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of social phobia with clonazepam and placebo</atitle><jtitle>Journal of clinical psychopharmacology</jtitle><addtitle>J Clin Psychopharmacol</addtitle><date>1993-12-01</date><risdate>1993</risdate><volume>13</volume><issue>6</issue><spage>423</spage><epage>428</epage><pages>423-428</pages><issn>0271-0749</issn><coden>JCPYDR</coden><abstract>Clonazepam and placebo were administered in a double-blind pilot study to 75 outpatients with social phobia. The mean maximum dose of clonazepam was 2.4 mg/day at endpoint (range, 0.5 to 3 mg). Treatment was continued for up to 10 weeks. The results of an intent-to-treat analysis indicated superior effects of clonazepam on most measures. Response rates for clonazepam and placebo were 78.3 and 20.0%. Drug effects were apparent on performance and generalized social anxiety, on fear and phobic avoidance, on interpersonal sensitivity, on fears of negative evaluation, and on disability measures. Significant differences were evident by week 1, 2, or 6, depending upon the rating scale used. Clonazepam was well tolerated in general, although unsteadiness and dizziness were more severe and persistent than was the case for placebo subjects.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>8120156</pmid><doi>10.1097/00004714-199312000-00008</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0271-0749 |
| ispartof | Journal of clinical psychopharmacology, 1993-12, Vol.13 (6), p.423-428 |
| issn | 0271-0749 |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00004714_199312000_00008 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Anxiety - drug therapy Biological and medical sciences Clonazepam - administration & dosage Clonazepam - adverse effects Clonazepam - therapeutic use Double-Blind Method Female Humans Male Medical sciences Neuropharmacology Pharmacology. Drug treatments Phobic Disorders - drug therapy Phobic Disorders - psychology Pilot Projects Psychiatric Status Rating Scales Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology |
| title | Treatment of social phobia with clonazepam and placebo |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T06%3A43%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20social%20phobia%20with%20clonazepam%20and%20placebo&rft.jtitle=Journal%20of%20clinical%20psychopharmacology&rft.au=DAVIDSON,%20J.%20R.%20T&rft.date=1993-12-01&rft.volume=13&rft.issue=6&rft.spage=423&rft.epage=428&rft.pages=423-428&rft.issn=0271-0749&rft.coden=JCPYDR&rft_id=info:doi/10.1097/00004714-199312000-00008&rft_dat=%3Cpubmed_cross%3E8120156%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8120156&rfr_iscdi=true |